- Home
- OBE vs ORGO Comparison
OBE vs ORGO Comparison
Compare OBE & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBE | ORGO |
|---|---|---|
| Founded | 1979 | 1985 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.9M | 514.0M |
| IPO Year | 2005 | 2016 |
Fundamental Metrics
Financial Performance| Metric | OBE | ORGO |
|---|---|---|
| Price | $8.48 | $2.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $7.67 |
| AVG Volume (30 Days) | 530.1K | ★ 661.5K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.32 | $17.84 |
| P/E Ratio | ★ N/A | $19.37 |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $3.88 | $2.61 |
| 52 Week High | $8.67 | $7.08 |
Technical Indicators
Market Signals| Indicator | OBE | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 64.23 | 24.47 |
| Support Level | $5.57 | $2.61 |
| Resistance Level | N/A | $3.28 |
| Average True Range (ATR) | 0.41 | 0.23 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 79.96 | 2.00 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.